Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-Drug Interaction Study of Quinidine and Orforglipron in Healthy Participants
NCT06704763Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orforglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity and Maximum Observed Concentration. Started Dec 2024; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06704763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704763.